The Asia Pacific SGLT2 inhibitors market size is expected treach USD 3,972.35 million by 2034, according ta new study by Polaris Market Research. The report “Asia Pacific SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease (CKD) Type 2 Diabetes, and Others), Drug, Distribution Channel, and Country (China, Japan, India, Malaysia, South Korea, Indonesia, Australia, Vietnam, and Rest of Asia Pacific) – Market Forecast, 2025– 2034” gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.
The SGLT2 inhibitors market in Asia Pacific is experiencing significant growth, driven by the rising prevalence of type 2 diabetes. Lifestyle changes, urbanization, and an aging population are contributing tincreased obesity rates and sedentary behaviors, leading ta higher risk of diabetes. As a result, there is a considerable focus on preventive healthcare measures, with governments and healthcare organizations actively promoting early diagnosis and effective management of diabetes.
The rapid economic growth in many Asia Pacific countries is leading tsubstantial improvements in healthcare infrastructure. Increased investment in healthcare facilities and rising disposable incomes are making advanced diabetes treatments more accessible, thereby driving the demand for healthcare services, including the use of SGLT2 inhibitors for diabetes management.
The Asia Pacific SGLT2 inhibitors market demand is further supported by the heightened awareness of the proven efficacy and additional benefits of SGLT2 inhibitors. These inhibitors are known for effectively reducing blood glucose levels, managing type 2 diabetes, promoting weight loss, and reducing the risk of cardiovascular events, making them a desirable option for both patients and healthcare providers.
Additionally, Asia Pacific has a large population with a high genetic predisposition tdiabetes, particularly in countries like India and China. This genetic susceptibility, combined with environmental factors, is contributing tthe growing demand for effective diabetes treatments, including SGLT2 inhibitors.
Key Highlights of Asia Pacific SGLT2 Inhibitors Market Report
Based on indication, the type 2 diabetes segment accounted for the largest revenue share in 2023. The rising number of type 2 diabetes cases in Asia Pacific due tchanging lifestyles, urbanization, and dietary habits is driving significant demand for effective diabetes management solutions, including SGLT2 inhibitors.
Based on distribution channel, the hospital pharmacies segment is projected tregister the fastest growth from 2024 t2032. With the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer, there is a growing need for comprehensive and continuous medical care. Hospital pharmacies play a crucial role in managing these conditions by providing necessary medications and ensuring proper drug administration.
In 2023, China accounted for the largest market share in the Asia Pacific SGLT2 inhibitors market due tgovernment initiatives, healthcare reforms, and heightened research and development efforts focused on diabetes management.
AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi, Pfizer Inc.; Lupin; and Cipla limited. are a few of the key players in the market.
Polaris Market Research has segmented the Asia Pacific SGLT2 inhibitors market research report on the basis of indication, drug, distribution channel, and country:
By Indication Outlook (Revenue – USD Million, 2020–2034)
Cardiovascular
Chronic Kidney Disease (CKD)
Type 2 Diabetes
Others
By Drug Outlook (Revenue – USD Mllion, 2020–2034)
Farxiga (Dapagliflozin)
Inpefa (Sotagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
Other SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue – USD Million, 2020–2034)
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country Outlook (Revenue – USD Million, 2020–2034)
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Asia SGLT2 Inhibitors Market Insights
- 4.1. SGLT2 Inhibitors Market – Market Snapshot
- 4.2. SGLT2 Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of Diabetes
- 4.2.1.2. The Rapid Urbanization
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory and Approval Barriers
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. SGLT2 Inhibitors Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Asia SGLT2 Inhibitors Market, by Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Asia SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 5.3. Cardiovascular
- 5.3.1. Asia SGLT2 Inhibitors Market, by Cardiovascular, by Country, 2020-2034 (USD Million)
- 5.4. Chronic Kidney Disease (CKD)
- 5.4.1. Asia SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Country, 2020-2034 (USD Million)
- 5.5. Type 2 Diabetes
- 5.5.1. Asia SGLT2 Inhibitors Market, by Type 2 Diabetes, by Country, 2020-2034 (USD Million)
- 5.6. Others
- 5.6.1. Asia SGLT2 Inhibitors Market, by Shaving Lotions & Creams, by Country, 2020-2034 (USD Million)
- 6. Asia SGLT2 Inhibitors Market, by Drug
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Asia SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 6.3. Farxiga (Dapagliflozin)
- 6.3.1. Asia SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Country, 2020-2034 (USD Million)
- 6.4. Inpefa (Sotagliflozin)
- 6.4.1. Asia SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Country, 2020-2034 (USD Million)
- 6.5. Invokana (Canagliflozin)
- 6.5.1. Asia SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Country, 2020-2034 (USD Million)
- 6.6. Jardiance (Empagliflozin)
- 6.6.1. Asia SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Country, 2020-2034 (USD Million)
- 6.7. Qtern (Dapagliflozin/Saxagliptin)
- 6.7.1. Asia SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Country, 2020-2034 (USD Million)
- 6.8. Other SGLT2 Inhibitors
- 6.8.1. Asia SGLT2 Inhibitors Market, by Other SGLT2 Inhibitors, by Country, 2020-2034 (USD Million)
- 7. Asia SGLT2 Inhibitors Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Asia SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Asia SGLT2 Inhibitors Market, by Hospital Pharmacies, by Country, 2020-2034 (USD Million)
- 7.4. Online Pharmacies
- 7.4.1. Asia SGLT2 Inhibitors Market, by Online Pharmacies, by Country, 2020-2034 (USD Million)
- 7.5. Retail Pharmacies
- 7.5.1. Asia SGLT2 Inhibitors Market, by Retail Pharmacies, by Country, 2020-2034 (USD Million)
- 8. Asia SGLT2 Inhibitors Market, by Country
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. SGLT2 Inhibitors Market Assessment, By Country, 2020-2034 (USD Million)
- 8.3. SGLT2 Inhibitors Market – Asia Pacific
- 8.3.1. Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.2. Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.3. Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.4. SGLT2 Inhibitors Market – China
- 8.3.4.1. China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.4.2. China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.4.3. China: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.5. SGLT2 Inhibitors Market – India
- 8.3.5.1. India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.5.2. India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.5.3. India: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.6. SGLT2 Inhibitors Market – Malaysia
- 8.3.6.1. Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.6.2. Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.6.3. Malaysia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.7. SGLT2 Inhibitors Market – Japan
- 8.3.7.1. Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.7.2. Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.7.3. Japan: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.8. SGLT2 Inhibitors Market – Indonesia
- 8.3.8.1. Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.8.2. Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.8.3. Indonesia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.9. SGLT2 Inhibitors Market – South Korea
- 8.3.9.1. South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.9.2. South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.9.3. South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.10. SGLT2 Inhibitors Market – Australia
- 8.3.10.1. Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.10.2. Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.10.3. Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.11. SGLT2 Inhibitors Market – Rest of Asia Pacific
- 8.3.11.1. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Million)
- 8.3.11.2. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Million)
- 8.3.11.3. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Million)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Boehringer Ingelheim International GmbH
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Glenmark Pharmaceuticals Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Johnson & Johnson Inc. (Janssen Pharmaceuticals, Inc.)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Lexicon Pharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Pfizer Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Lupin
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Cipla Limited
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook